Company profile: Longeveron
1.1 - Company Overview
Company description
- Provider of cellular therapies and research programs, developing Lomecel-B, a culture-expanded medicinal signaling cell (MSC) therapy for aging-related diseases, Alzheimer’s disease, and hypoplastic left heart syndrome (HLHS), with programs testing its use in aging frailty, metabolic syndrome, and acute respiratory distress syndrome (ARDS) due to COVID-19 or influenza.
Products and services
- Aging Frailty Research Program: An investigational program evaluating Lomecel-B’s ability to improve physical function, reduce inflammation, and enhance quality of life in aging frailty patients using culture-expanded MSC-derived therapy
- Alzheimer’s Disease Research Program: An investigational initiative utilizing Lomecel-B to potentially reduce brain inflammation and promote regenerative responses in Alzheimer’s disease through culture-expanded medicinal signaling cells (MSCs)
- Lomecel-B: A culture-expanded MSC-based cellular therapy engineered to treat aging-related diseases, Alzheimer’s disease, and hypoplastic left heart syndrome (HLHS) with medicinal signaling cell characteristics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Longeveron
DalCor Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmacogenetic precision treatments for cardiovascular disease targeting patients with the ADCY9 AA genotype, including dalcetrapib; the completed Dal-GenE (DAL-301) cardiovascular outcomes trial; the Phase 3 Dal-GenE-2 (DAL-302) trial evaluating dalcetrapib’s potential to reduce fatal and non-fatal myocardial infarction; and the cobas ADCY9 genotype companion diagnostic developed with Roche Molecular Systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DalCor Pharmaceuticals company profile →
Xenios
HQ: Germany
Website
- Description: Provider of extracorporeal therapy systems delivering minimally invasive disposable lung and heart therapies on a single platform, including the Xenios Console for ECLS in heart and lung failure; MultiSupport GROUND for ground transport requiring extracorporeal gas exchange or circulatory support; Novalung Kits with integrated pressure sensors for blood gas exchange; and iLA activve Kits for gas exchange and temperature control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenios company profile →
Apama Medical
HQ: United States
Website
- Description: Provider of medical devices for the electrophysiology (EP) market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apama Medical company profile →
Kalila Medical
HQ: United States
Website
- Description: Provider of specialized catheters for vascular and intracardiac access, developing a platform including steerable sheaths for catheter-based atrial fibrillation ablation. Compatible with 8Fr and 12Fr ablation catheters, the Kalila sheath provides superior torque and tip.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kalila Medical company profile →
BioTrace Medical
HQ: United States
Website
- Description: Provider of temporary cardiac pacing solutions, including the Tempo Lead, a temporary pacing lead designed to minimize the risk of myocardial perforation, provide stable pacing, and enable early patient mobilization after procedures such as TAVR, aiming to improve patient outcomes and reduce hospital costs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioTrace Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Longeveron
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Longeveron
2.2 - Growth funds investing in similar companies to Longeveron
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Longeveron
4.2 - Public trading comparable groups for Longeveron
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →